CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
Oncotarget
.
2018 Sep 28;9(76):34193-34195.
doi: 10.18632/oncotarget.26134.
Authors
Clinton Yam
1
,
Mien-Chie Hung
1
,
Gabriel N Hortobagyi
1
Affiliation
1
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
PMID:
30344934
PMCID:
PMC6188130
DOI:
10.18632/oncotarget.26134
No abstract available
Keywords:
CDK4/6 inhibitors; hormone receptor-positive; metastatic breast cancer.
Publication types
Editorial